- CHA Biotech’s subsidiary Matica Biolabs has signed a CDMO agreement with TiCARos to manufacture clinical trial material for its solid tumour–targeted CAR-T candidate, TC091.
- Matica Biolabs said it aims to use the project to expand its solid tumour cell therapy capabilities and is pursuing additional CDMO contracts.
CHA Biotech’s CDMO subsidiary Matica Biolabs has signed a contract development and manufacturing deal with TiCARos to produce clinical trial material for the biotech’s solid tumour–focused CAR-T therapy. The agreement centres on TC091, a candidate built on TiCARos’ proprietary CLIP CAR platform, which the company says is intended to enhance tumour-killing activity and safety.
The programme has been selected for several domestic support initiatives, including the Korea Drug Development Fund’s drug candidate project, the fund’s 2024 R&D ecosystem development programme and the Ministry of Food and Drug Safety’s Bio Challenger programme in July 2025. Matica Biolabs said the collaboration aligns with its plans to strengthen its cell and gene therapy contract manufacturing pipeline.
“The company expects ‘significant synergy’ from combining TiCARos’ CAR-T platform with Matica’s process development and manufacturing capabilities. The CDMO intends to use the project to expand its position in solid tumour cell therapies.”
Chief Executive Officer Jang Won-gyu
Matica Biolabs was spun out of CHA Biotech in 2018 and previously operated as CHA Biolab. It focuses on CDMO work in Korea, while sister company Matica Biotechnology manages North American and global contracts. The subsidiary said it is pursuing additional CDMO agreements and is targeting two to three more deals by the end of the year.
